Antibody-Mediated Delivery of Anti– KRAS -siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Purpose: KRAS mutations are frequent driver mutations in multiple cancers. KRAS mutations also induce anti-EGFR antibody resistance in adenocarcinoma such as colon cancer. The aim of this study was to overcome anti-EGFR antibody resistance by coupling the antibody to KRAS-specific siRNA. Experimental Design: The anti-EGFR antibody was chemically coupled to siRNA. The resulting complex was tested for antibody binding efficiency, serum stability and ability to deliver siRNA to EGFR-expressing cells. Western blotting, viability, apoptosis, and colony formation assays were performed for efficacy evaluation in vitro. Furthermore, therapeutic activity of the antibody–KRAS-siRNA complexes was examined in in vivo xenograft mouse tumor models. Results: Antibody–siRNA complexes were targeted and internalized via the EGFR receptor. Upon internalization, target gene expression was strongly and specifically repressed, followed by a reduced proliferation and viability, and induced apoptosis of the cells in vitro. Clonogenic growth of mutant KRAS-bearing cells was suppressed by KRAS-siRNA–anti-EGFR antibody complexes. In xenograft mouse models, anti-EGFR antibody–KRAS-siRNA complexes significantly slowed tumor growth in anti-EGFR–resistant cells. Conclusions: The coupling of siRNA against KRAS to anti-EGFR antibodies provides a novel therapy approach for KRAS-mutated EGFR-positive cancer cells in vitro and in vivo. These findings provide an innovative approach for cancer-specific siRNA application and for enhanced therapeutic potential of monoclonal antibody therapy and personalized treatment of cancer entities. Clin Cancer Res; 21(6); 1383–94. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“The coupling of trastuzumab to the cytotoxic drug emtansine (TDM1) has shown significant clinical activity even in trastuzumab-resistant breast cancers (51).”
BackgroundCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“Also in patients that develop anti-EGFR antibody resistance over time, the outgrowth of clones with KRAS mutations appears to be the predominant mode of resistance (20).”
BackgroundBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 1×
“Also, only approximately 10% of xenografts transplanted from patientderived, metastatic colorectal cancer samples showed tumor reduction upon cetuximab treatment (42).”
BackgroundJänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460 · cited 2×
“Interestingly, HCT116 cells contain a PIK3CA activating mutation H1047R besides the KRAS G13D activating mutation (34, 35).”
BackgroundMutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295 · cited 1×
“A recent publication underlines the importance to targetKRASwith siRNA: Here, the authors chose to apply KRAS siRNA with the help of miniature polymer capsules locally implanted to xenografted pancreatic tumors (47).”
Background
Cited by
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
Kim, B., Park, J., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201903637 · Cited by 298
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth
Kim, W., Lee, S., Kim, H. S., Song, M., Cha, Y. H., Kim, Y.-H., Shin, J., Lee, E.-S., Joo, Y., Song, J. J., et al. (2018) · Genome Research · doi:10.1101/gr.223891.117 · Cited by 97
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
Metadata
- Authors
- Bäumer, S., Bäumer, N., Appel, N., Terheyden, L., Fremerey, J., Schelhaas, S., Wardelmann, E., Buchholz, F., Berdel, W. E., & Müller-Tidow, C.
- Venue
- Clinical Cancer Research
- Published
- 2015-03-12
- Volume
- 21
- Issue
- 6
- Pages
- 1383-1394
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2001054044
- Cited by
- 119
- References
- 12
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody-Mediated Delivery of Anti– KRAS -siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2017
- The paper
- Bäumer, S., Bäumer, N., Appel, N., Terheyden, L., Fremerey, J., Schelhaas, S., Wardelmann, E., Buchholz, F., Berdel, W. E., & Müller-Tidow, C. (2015). Antibody-Mediated Delivery of Anti– KRAS -siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.